treatment with RIB5/2 even accelerated the onset of AA by approximately 2 days (day 10), and ameliorated the arthritis only in the late phase (day 27)|preventive treatment with OX35 and W3/25 significantly ameliorated AA from the onset|(day 10)|preventive treatment with OX35 and W3/25 significantly ameliorated AA from the onset|1061..1211|975..1059|1140..1148|975..1059|111020.txt|969..974|SS
and more strongly induced NF-κB binding activity|anti-CD4 preincubation and subsequent TCR/CD3-stimulation|paralleled by a differential influence of the mAbs on T-cell functions|anti-CD4 preincubation and subsequent TCR/CD3-stimulation|1561..1609|1616..1673|1267..1337|1616..1673|111020.txt|1610..1615|SS
CD4+ T cells and their cytokine products play an important role in rheumatoid arthritis and experimental models of arthritis|representing potential therapeutic targets [1]|IntroductionCD4|representing potential therapeutic targets [1|1997..2121|2133..2179|1983..2000|2133..2178|111020.txt|2123..2132|SS
Anti-CD4 mAbs induce either cell depletion [2] or functional inactivation of T cells [3,4]|activation of T-cell functions has also been reported [5]|3,4|activation of T-cell functions has also been reported [5|2320..2410|2421..2478|2406..2409|2421..2477|111020.txt|2412..2420|SS
T-cell reactivity was measured in vivo by delayed-type hypersensitivity (DTH) and in vitro by proliferation assay or mixed lymphocyte culture|cytokines were measured by bioassay or ELISA (see Supplementary material; for tumor necrosis factor (TNF)-α [15])|T-cell reactivity|cytokines were measured by bioassay or ELISA (see Supplementary material; for tumor necrosis factor (TNF)-α [15])|3778..3919|3925..4038|3778..3795|3925..4038|111020.txt|3921..3924|SS
The accelerating effect of the mAb RIB5/2 was reproduced in two additional treatment experiments|this effect was observed despite a variable onset of AA in the PBS-treated animals (day 9 to 11)|The accelerating effect of the mAb RIB5/2|this effect was observed despite a variable onset of AA in the PBS-treated animals (day 9 to 11); i.e. in all experiments, the onset of AA occurred 2 days earlier than in the controls|4857..4953|4959..5055|4857..4898|4959..5142|111020.txt|4955..4958|SS
For the sake of simplicity, we refer to the mAb RIB5/2 as 'accelerating'|this term is applicable only to the onset of AA|the mAb RIB5/2 as 'accelerating|this term is applicable only to the onset of AA|5344..5416|5427..5474|5384..5415|5427..5474|111020.txt|5418..5426|SS
striking differences (up to 40-fold) were observed for the dissociation rate constants (kdiss)|the association rate constants (kass) for all three mAbs were within the same order of magnitude|(kdiss)|the association rate constants (kass) for all three mAbs were within the same order of magnitude|5826..5920|5728..5824|5913..5920|5728..5824|111020.txt|5722..5727|SS
Thus the accelerating mAb RIB5/2 displayed the highest kdiss|differences in overall affinity did not match differential clinical efficacy|Thus|differences in overall affinity did not match differential clinical efficacy|5922..5926;6015..6070|5937..6013|5922..5926|5937..6013|111020.txt|5928..5936|SS
The other ameliorating anti-CD4 mAb, W3/25, also induced an increase|statistical significance was not reached|The other ameliorating anti-CD4 mAb, W3/25|statistical significance was not reached|6426..6494|6500..6540|6426..6468|6500..6540|111020.txt|6496..6499|SS
In the mixed lymphocyte culture, RIB5/2 was also the most potent inhibitor of T-cell activation in the case of total T cells|this was not observed in purified CD4+ T cells (Supplementary Fig. 4)|this|In the mixed lymphocyte culture, RIB5/2 was also the most potent inhibitor of T-cell activation in the case of total T cells this was not observed in purified CD4+ T cells (Supplementary Fig. 4)|6838..6962|6973..7042|6973..6977|6838..6962;6973..7042|111020.txt|6964..6971|SS
and stimulated with plate-bound anti-T-cell-receptor (TCR) α/β mAb (so called anti-CD4 preincubation)|cross-linking|To simulate the preventive therapeutic application in AA, i.e. the activation of CD4+ T cells in the presence of anti-CD4 mAbs|cross-linking|7236..7239;7262..7359|7247..7260|7046..7172|7247..7260|111020.txt|7241..7246|SS
the influence of these mAbs on early signaling events was also investigated|the three anti-CD4 mAbs recognize distinct epitopes of the CD4 molecule, which is involved in signaling cascades|distinct epitopes of the CD4 molecule, which is involved in signaling cascades|the three anti-CD4 mAbs recognize distinct epitopes of the CD4 molecule, which is involved in signaling cascades|7954..8029|7840..7952|7874..7952|7840..7952|111020.txt|7832..7839|SS
there is no evidence for a differential efficacy of anti-CD4 mAbs in arthritis models to date|successful treatment with anti-CD4 mAbs has been achieved in various arthritis models [12,16-18]|successful treatment|successful treatment with anti-CD4 mAbs has been achieved in various arthritis models [12,16-18|9556..9649|9458..9554|9458..9478|9458..9553|111020.txt|9449..9457|SS
The ameliorating mAb W3/25 had a very high affinity, as previously reported [20]|the affinity of the other ameliorating mAb, OX35, was comparable to that of the accelerating mAb, RIB5/2|RIB5/2|the affinity of the other ameliorating mAb, OX35, was comparable to that of the accelerating mAb|10062..10142|10152..10256|10250..10256|10152..10248|111020.txt|10144..10151|SS
we could roughly localize the epitope of RIB5/2 in the F–G region of domain D1, as demonstrated by effective competition with the mAb OX65 (data not shown), known to bind this region of the CD4 molecule [23]|the binding sites of W3/25 and OX35 are situated in the C´–C´´ region of domain D1 and the B–C region of domain D2 of the CD4 molecule, respectively [23]|of the CD4 molecule|the binding sites of W3/25 and OX35 are situated in the C´–C´´ region of domain D1 and the B–C region of domain D2 of the CD4 molecule, respectively [23|10885..11092|10730..10883|10845..10864|10730..10882|111020.txt|10724..10729|SS
both upon anti-CD4 preincubation and upon CD4 cross-linking|stimulation with TCR (see Fig. 2)|observed in primary CD4+ T cells|stimulation|12730..12789|12796..12829|12697..12729|12796..12807|111020.txt|12790..12795|SS
the acceleration of the onset of AA|pretreatment with the mAb RIB5/2|In view of the known local and systemic importance of TNF-α in experimental AA [28-30] and human rheumatoid arthritis [31|pretreatment with the mAb RIB5/2|12985..13020|13027..13059|12831..12952|13027..13059|111020.txt|13021..13026|SS
This finding may be important for the understanding of pathogenesis in arthritis despite predominant production of TNF-α by macrophages/monocytes (reviewed in [32])|TNF-α production by T cells has been demonstrated both in the synovial membrane [33] and in lymphoid organs (authors own unpublished observations)|TNF-α production|TNF-α production by T cells has been demonstrated both in the synovial membrane [33] and in lymphoid organs (authors own unpublished observations)|13061..13225|13233..13379|13233..13249|13233..13379|111020.txt|13227..13232|SS
it was revealing that the accelerating mAb, RIB5/2, besides inducing TNF-α secretion, also strongly upregulated NF-κB binding activity|TNF-α production is known to be regulated predominantly by NF-κB [34]|known to be regulated predominantly by NF-κB [34|TNF-α production is known to be regulated predominantly by NF-κB [34|13460..13594|13389..13458|13409..13457|13389..13457|111020.txt|13383..13388|SS
it is a very effective anti-CD4 mAb for the induction of tolerance in transplantation models [14,37]|preventive treatment with the anti-CD4 mAb RIB5/2 leads to an acceleration of AA|However|preventive treatment with the anti-CD4 mAb RIB5/2 leads to an acceleration of AA|14289..14389|14207..14287|14192..14199|14207..14287|111020.txt|14201..14206|SS
that clinical efficacy (and its time course) may depend on the actual immunological constellation|that a given anti-CD4 mAb may have beneficial effects only in particular pathologies and/or stages of disease|clinical efficacy (and its time course)|that a given anti-CD4 mAb may have beneficial effects only in particular pathologies and/or stages of disease|14406..14503|14508..14617|14411..14450|14508..14617|111020.txt|14504..14507|SS
the individual features and effects of a particular anti-CD4 mAb have to be assessed|treatment trials|in order to predict its clinical efficacy in vivo|treatment trials|14677..14761|14769..14785|14786..14835|14769..14785|111020.txt|14762..14768|SS
The data were analyzed in accordance with the method of Karlsson et al.[S1]|the association rate constant kass, the dissociation rate constant kdiss, and the affinity constant KA (kass/kdiss) were calculated|The data|the association rate constant kass, the dissociation rate constant kdiss, and the affinity constant KA (kass/kdiss) were calculated|17577..17652|17658..17789|17577..17585|17658..17789|111020.txt|17654..17657|SS
Briefly, the spleens were passed through a stainless steel sieve|the resulting suspension was centrifuged through Lymphoprep (Pharmacia)|Briefly|the resulting suspension was centrifuged through Lymphoprep (Pharmacia)|20158..20222|20227..20298|20158..20165|20227..20298|111020.txt|20223..20226|SS
the cells were eluted with RPMI 1640/GlutaMaxI con- taining 10% FCS, 15 mM HEPES, 100 U/ml penicillin, and 100 μg/ml streptomycin (thereafter called R10F, all from GIBCO-BRL, Eggenstein, Germany)|incubation for 1 hour at 37°C, 5% CO2|for 1 hour at 37°C, 5% CO2|incubation for 1 hour at 37°C, 5% CO2|20491..20686|20452..20489|20463..20489|20452..20489|111020.txt|20446..20451|SS
purified total T cells were directly used for proliferation assays|CD4+ T cells were first negatively purified by adding 5 μg/1×107 cells OX8 mAb for 30 min on ice and, after washing, 75 μl Dynabeads-M450 coupled to goat anti-mouse IgG (Dynal, Hamburg, Germany)|purified total T cells|CD4+ T cells were first negatively purified by adding 5 μg/1×107 cells OX8 mAb for 30 min on ice and, after washing, 75 μl Dynabeads-M450 coupled to goat anti-mouse IgG (Dynal, Hamburg, Germany)|20781..20847|20852..21046|20781..20803|20852..21046|111020.txt|20774..20780;20849..20851|SS
and 75 μl Dynabeads-M450 coupled to goat anti-mouse IgG (Dynal, Hamburg, Germany)|washing|Either purified total T cells were directly used for proliferation assays|washing, 75 μl Dynabeads-M450 coupled to goat anti-mouse IgG (Dynal, Hamburg, Germany)|20949..20952;20969..21046|20960..20967|20774..20847|20960..21046|111020.txt|20954..20959|SS
The suspension was again incubated for 30 min on ice|and separated by a magnetic particle concentrator (MPC®, Dynal)|The suspension|incubated for 30 min on ice and separated by a magnetic particle concentrator (MPC®, Dynal)|21048..21100|21101..21104;21110..21169|21048..21062|21073..21104;21110..21169|111020.txt|21105..21109|SS
suspensions of spleen cells from healthy rats were subjected to an overnight adhesion step on Petri dishes (Falcon®, Becton Dickinson, Heidelberg, Germany)|and centrifuged through 2 ml of a 14.5% metrizamide solution (Sigma) in R10F|For enrichment of dendritic cells (DC)|subjected to an overnight adhesion step on Petri dishes (Falcon®, Becton Dickinson, Heidelberg, Germany) and centrifuged through 2 ml of a 14.5% metrizamide solution (Sigma) in R10F|21298..21453|21454..21457;21463..21535|21258..21296|21349..21457;21463..21535|111020.txt|21458..21462|SS
cells were harvested onto fiber filters and cell-bound radioactivity was measured by β-scintillation counting (Matrix96®, Canberra Packard, Dreieich, Germany)|an additional incubation for 16 hours|for 16 hours|an additional incubation for 16 hours|21943..22101|21904..21941|21929..21941|21904..21941|111020.txt|21898..21903|SS
bromodeoxyuridine (BrdU) was added and incubation was continued for an additional 16 hours|incubation for 72 hours (37°C, 5% CO2)|37°C|incubation for 72 hours (37°C, 5% CO2)|22535..22625|22495..22533|22520..22524|22495..22533|111020.txt|22489..22494|SS
bromodeoxyuridine (BrdU) was added|incubation was continued for an additional 16 hours|After incubation for 72 hours (37°C, 5% CO2)|incubation was continued for an additional 16 hours|22535..22569|22574..22625|22489..22533|22574..22625|111020.txt|22570..22573|SS
the cells (1 × 106 per ml and per well) were seeded in 24-well plates previously coated with R73 and harvested after 24 and 48 hours|washing|(1 × 106 per ml and per well)|washing|23093..23225|23084..23091|23103..23132|23084..23091|111020.txt|23078..23083|SS
Purified spleen CD4+ T cells were preincubated with the anti-CD4 mAbs as above|and either stimulated on anti-CD3 mAb-precoated 6-well plates (1 × 107 cells per well) or with a combination of phorbol myristoyl acetate (PMA; 10 ng/ml) and ionomycin (250 ng/ml) for 4 hours at 37°C|Purified spleen CD4+ T cells|Purified spleen CD4+ T cells were preincubated with the anti-CD4 mAbs as above and either stimulated on anti-CD3 mAb-precoated 6-well plates (1 × 107 cells per well) or with a combination of phorbol myristoyl acetate (PMA; 10 ng/ml) and ionomycin (250 ng/ml) for 4 hours at 37°C|24367..24445|24446..24449;24455..24650|24367..24395|24367..24449;24455..24650|111020.txt|24450..24454|SS
the cells were washed once with PBS and microcentrifuged (10,000 × g) at 4°C for 1 min|stimulation|the cells|stimulation|24671..24757|24658..24669|24671..24680|24658..24669|111020.txt|24652..24657|SS
Subsequently, 25 μl of a 10% Nonidet P-40 solution (Boehringer Mannheim) were added to the sample|the cells were homogenized by vortexing for 30 s followed by microcentrifugation for 1 min|Subsequently|the cells were homogenized by vortexing for 30 s followed by microcentrifugation for 1 min|24946..25043|25048..25138|24946..24958|25048..25138|111020.txt|25044..25047|SS
the supernatants were aliquoted and stored at -70°C until further use|microcentrifugation for 5 min at 4°C|for 5 min at 4°C|microcentrifugation for 5 min at 4°C|25374..25443|25336..25372|25356..25372|25336..25372|111020.txt|25330..25335|SS
the supernatants were aliquoted and stored at -70°C|further use|After microcentrifugation for 5 min at 4°C|further use|25374..25425|25432..25443|25330..25372|25432..25443|111020.txt|25426..25431|SS
the bands were quantified using the PCBAS 2.09g software (Fuij Photo Film Co. Ltd)|scanning in a phosphor imager (BAS-1000, Fuij Photo Film Co. Ltd, Japan)|in a phosphor imager (BAS-1000, Fuij Photo Film Co. Ltd, Japan)|scanning in a phosphor imager (BAS-1000, Fuij Photo Film Co. Ltd, Japan)|26108..26190|26034..26106|26043..26106|26034..26106|111020.txt|26028..26033|SS
The in vitro proliferation rates of total T cells from OX35- and W3/25-treated animals in response to polyspecific stimulation with ConA were higher than those of PBS-treated rats|T cells of the RIB5/2-treated rats showed proliferation rates similar to those of T cells from PBS-treated animals (Supplementary Fig. 2)|The in vitro proliferation rates of total T cells from OX35- and W3/25-treated animals in response to polyspecific stimulation with ConA|T cells of the RIB5/2-treated rats showed proliferation rates similar to those of T cells from PBS-treated animals (Supplementary Fig. 2)|26640..26819|26827..26964|26640..26776|26827..26964|111020.txt|26821..26826|SS
The accelerating mAb RIB5/2 led to significant inhibition at all concentrations of mAb (1, 5, and 10 μg/ml; only 1 μg/ml is shown in Supplementary Fig. 4a) and DC|the other two anti-CD4 mAbs significantly inhibited the proliferation only in some cases|significantly|the other two anti-CD4 mAbs significantly inhibited the proliferation only in some cases|27887..28049|28059..28147|28087..28100|28059..28147|111020.txt|28051..28058|SS
They showed a clearer inhibition of their proliferation rates (50 to 80% in comparison with the isotype)|used as responder cells|They|used as responder cells|28620..28724|28730..28753|28620..28624|28730..28753|111020.txt|28725..28729|SS
the percentage and/or MFI (mean fluorescence intensity) of CD3+ cells in the peripheral blood on days 8 and 13 was numerically lower than in the PBS-treated control group, resulting in a significantly lower MFI on day 13|treatment with W3/25|the percentage and/or MFI (mean fluorescence intensity)|treatment with W3/25|29338..29558|29316..29336|29338..29393|29316..29336|111020.txt|29310..29315|SS
Furthermore, a decrease of CD4+ cells was observed|the cells were stained with OX35 (more prominent on day 13; see Supplementary Table 2B)|a decrease of CD4+ cells|the cells were stained with OX35 (more prominent on day 13; see Supplementary Table 2B)|29695..29745|29751..29838|29708..29732|29751..29838|111020.txt|29746..29750|SS
only 7% (day 8) and 28% (day 13) of the peripheral blood mononuclear cells were CD4+|ex vivo staining with W3/25 – the mAb also used for treatment|CD4|ex vivo staining with W3/25 the mAb also used for treatment only 7% (day 8) and 28% (day 13) of the peripheral blood|29910..29994|29846..29907|29990..29993|29846..29873;29876..29907;29910..29966|111020.txt|29840..29845|SS
the percentage of CD8+ cells did not show any significant changes on days 8 or 13|treatment with W3/25|the percentage|treatment with W3/25|30250..30331|30228..30248|30250..30264|30228..30248|111020.txt|30222..30227|SS
After treatment with W3/25, the percentage of CD8+ cells did not show any significant changes on days 8 or 13|the MFI for CD8 on day 13 was significantly decreased (see Supplementary Table 2B)|the MFI for CD8 on day 13|After treatment with W3/25, the percentage of CD8+ cells did not show any significant changes on days 8 or 13 the MFI for CD8 on day 13 was significantly decreased (see Supplementary Table 2B)|30222..30331|30342..30424|30342..30367|30222..30331;30342..30424|111020.txt|30333..30340|SS
The percentage of CD8+ cells of OX35-treated rats was either significantly or numerically increased compared to the PBS-treated control on day 8 or 13, respectively|the MFI of the CD8 molecule was significantly decreased on both days|to the PBS-treated control on day 8 or 13|the MFI of the CD8 molecule was significantly decreased on both days|31295..31459|31469..31537|31404..31445|31469..31537|111020.txt|31461..31468|SS
Similarly to the findings for mAb OX35, mAb RIB5/2 induced T-cell depletion and CD4 modulation|the degree of peripheral T-cell depletion was stronger than in the case of OX35|the degree of peripheral T-cell depletion|Similarly to the findings for mAb OX35, mAb RIB5/2 induced T-cell depletion and CD4 modulation the degree of peripheral T-cell depletion was stronger than in the case of OX35|32312..32406|32417..32496|32417..32458|32312..32406;32417..32496|111020.txt|32408..32415|SS
Thus there was no apparent match of these parameters with the clinical efficacy|both ameliorating and accelerating mAbs (OX35 and RIB5/2) depleted CD4+ T cells from peripheral blood, and since all three mAbs were modulating|both ameliorating and accelerating mAbs|both ameliorating and accelerating mAbs (OX35 and RIB5/2) depleted CD4+ T cells from peripheral blood|32500..32504;32657..32731|32512..32655|32512..32551|32512..32613|111020.txt|32506..32511|SS
since both ameliorating and accelerating mAbs (OX35 and RIB5/2) depleted CD4+ T cells from peripheral blood|since all three mAbs were modulating|all three mAbs|since all three mAbs were modulating|32506..32613|32619..32655|32625..32639|32619..32655|111020.txt|32615..32618|SS
At 24 h, a numerical increase of the percentage of IL-10-positive cells could be detected|preincubation with the ameliorating mAb W3/25 and the accelerating mAb RIB5/2|At 24 h|preincubation|33627..33716|33723..33800|33627..33634|33723..33736|111020.txt|33717..33722|SS
At 24 h, a numerical increase of the percentage of IL-10-positive cells could be detected after preincubation with the ameliorating mAb W3/25 and the accelerating mAb RIB5/2|the other ameliorating mAb, OX35, induced a significant increase (Supplementary Fig. 5g)|(Supplementary Fig. 5g)|the other ameliorating mAb, OX35, induced a significant increase (Supplementary Fig. 5g)|33627..33800|33810..33898|33875..33898|33810..33898|111020.txt|33802..33809|SS
mAb, RIB5/2 and OX35 were moderately or strongly depleting and modulating mAbs, respectively|W3/25 was a weakly depleting, but clearly modulating|RIB5/2 and OX35|W3/25 was a weakly depleting, but clearly modulating, mAb|35060..35152|35006..35058|35065..35080|35006..35063|111020.txt|34998..35005|SS
the use of the terms 'depleting' or 'nondepleting' has to be restricted to the blood|depletion/modulation in peripheral blood may differ from that in other compartments (e.g. lymphoid organs)|depletion/modulation|depletion/modulation in peripheral blood may differ from that in other compartments (e.g. lymphoid organs)|35480..35564|35372..35478|35372..35392|35372..35478|111020.txt|35364..35371|SS
IL-10 secretion was strikingly induced by all three anti-CD4 mAbs|IFN-γ secretion was completely unaffected by anti-CD4 preincubation and IL-4 was only increased by the mAb W3/25 (as previously reported; [S10])|IFN-γ secretion was completely unaffected by anti-CD4 preincubation|IFN-γ secretion was completely unaffected by anti-CD4 preincubation and IL-4 was only increased by the mAb W3/25 (as previously reported; [S10])|36860..36925|36714..36858|36714..36781|36714..36858|111020.txt|36706..36713|SS
upregulation is achieved by Th1 cytokines|Th2-derived cytokines are mostly inhibitory [11]|upregulation|Th2-derived cytokines are mostly inhibitory [11|2543..2584|2592..2640|2543..2555|2592..2639|111021.txt|2586..2591|SS
and kept in aliquots at -70°C|use|rTF preparation|use|3945..3974|3981..3984|3840..3855|3981..3984|111021.txt|3975..3980|SS
No significant difference in the results obtained with these two preparations was observed|the results were thus pooled|with these two preparations|the results were thus pooled|4100..4190|4195..4223|4150..4177|4195..4223|111021.txt|4191..4194|SS
Histological examination of joints was done|paraffin embedding, cutting, and staining with hematoxylin and eosin|Histological examination|paraffin|5645..5688|5695..5763|5645..5669|5695..5703|111021.txt|5689..5694|SS
Serial cryosections of 6 μm thickness were stained with rat monoclonal antibodies directed against mouse CD11b (Mac-1; M 1/70) or CD4 (GK1.5) (both antibodies from PharMingen, San Diego, CA, USA)|incubated with biotinylated secondary antibodies (DAKO A/S, Gosulp, Denmark) and avidin-biotin-peroxidase complexes (ABC)|rat monoclonal antibodies|incubated with biotinylated secondary antibodies (DAKO A/S, Gosulp, Denmark) and avidin-biotin-peroxidase complexes (ABC)|6211..6406|6413..6534|6267..6292|6413..6534|111021.txt|6408..6412|SS
The highest frequency of arthritis and severity of inflammation was observed on day 4 after injection|it diminished significantly by days 14 and 60 (13/15 versus 2/8 and 2/6, P < 0.05; Fig. 1a,b)|The highest frequency of arthritis and severity of inflammation|it diminished significantly by days 14 and 60 (13/15 versus 2/8 and 2/6, P < 0.05; Fig. 1a,b)|9264..9365|9370..9463|9264..9327|9370..9463|111021.txt|9366..9369|SS
Mice injected with etoposide|and deprived of monocyte/macrophage cell population|Mice|injected with etoposide, and deprived of monocyte/macrophage cell population|10735..10763|10765..10768;10777..10824|10735..10739|10740..10768;10777..10824|111021.txt|10769..10776|SS
The effects on T-cell reactivity in vivo (delayed-type hypersensitivity), ex vivo (ConA-induced proliferation), and in vitro (mixed lymphocyte culture) were assessed|The in vitro effects of anti-CD4 preincubation on T-cell receptor (TCR)/CD3-induced cytokine production and signal transduction were analyzed|The effects on T-cell reactivity in vivo (delayed-type hypersensitivity), ex vivo (ConA-induced proliferation), and in vitro (mixed lymphocyte culture) were assessed|The in vitro effects of anti-CD4 preincubation on T-cell receptor (TCR)/CD3-induced cytokine production and signal transduction were analyzed|654..819|821..953;959..967|654..819|821..953;959..967|111020.txt|954..958|PS
They are equally effective in suppressing AA upon treatment of established disease [11,12] (and authors own unpublished observations)|preventive treatment with the anti-CD4 mAbs W3/25, OX35, and RIB5/2 (on days -1, 0, 3, and 6, i.e. 1 day before AA induction, on the day of induction [day 0], and thereafter) had opposite effects in the induction phase of AA|They are equally effective in suppressing AA upon treatment of established disease [11,12] (and authors own unpublished observations)|preventive treatment with the anti-CD4 mAbs W3/25, OX35, and RIB5/2 (on days -1, 0, 3, and 6, i.e. 1 day before AA induction, on the day of induction [day 0], and thereafter) had opposite effects in the induction phase of AA|3183..3316|3331..3555|3183..3316|3331..3555|111020.txt|3318..3329|PS
Preventive treatment with the anti-CD4 mAbs W3/25 and OX35 led to a marked, significant suppression of the arthritis score from day 13 to 30 in comparison with PBS-treated animals (P ≤ 0.05; Fig. 1)|the anti-CD4 mAb RIB5/2 significantly accelerated the onset of the arthritis by approximately 2 days (P ≤ 0.01; days 11, 12; see Fig. 1), resulting in an aggravated clinical score on these days, and ameliorated clinical signs only from day 27 (P ≤ 0.05; see Fig. 1)|ResultsPreventive treatment with the anti-CD4 mAbs W3/25 and OX35 led to a marked, significant suppression of the arthritis score from day 13 to 30 in comparison with PBS-treated animals (P ≤ 0.05; Fig. 1)|the anti-CD4 mAb RIB5/2 significantly accelerated the onset of the arthritis by approximately 2 days (P ≤ 0.01; days 11, 12; see Fig. 1), resulting in an aggravated clinical score on these days, and ameliorated clinical signs only from day 27 (P ≤ 0.05; see Fig. 1)|4377..4575|4590..4855|4368..4575|4590..4855|111020.txt|4577..4588|PS
Calculation of the affinity constant (KA) resulted in comparable values for OX35 and RIB5/2 (see Supplementary Table 1)|the affinity of W3/25 was 50-fold that for the two other mAbs|Calculation of the affinity constant (KA) resulted in comparable values for OX35 and RIB5/2 (see Supplementary Table 1)|the affinity of W3/25 was 50-fold that for the two other mAbs|5525..5644|5659..5720|5525..5644|5659..5720|111020.txt|5646..5657|PS
Calculation of the affinity constant (KA) resulted in comparable values for OX35 and RIB5/2 (see Supplementary Table 1). In contrast, the affinity of W3/25 was 50-fold that for the two other mAbs. While the association rate constants (kass) for all three mAbs were within the same order of magnitude, striking differences (up to 40-fold) were observed for the dissociation rate constants (kdiss)|although differences in overall affinity did not match differential clinical efficacy, the accelerating mAb RIB5/2 displayed the highest kdiss|While the association rate constants (kass) for all three mAbs were within the same order of magnitude, striking differences (up to 40-fold) were observed for the dissociation rate constants (kdiss)|although differences in overall affinity did not match differential clinical efficacy, the accelerating mAb RIB5/2 displayed the highest kdiss|5525..5920|5928..6070|5722..5920|5928..6070|111020.txt|5922..5926|PS
Compared to the PBS-treated control group, the ameliorating mAb OX35 induced a significant increase of the DTH in response to the arthritogen Mycobacterium tuberculosis (Supplementary Fig. 1). The other ameliorating anti-CD4 mAb, W3/25, also induced an increase, but statistical significance was not reached|treatment with the accelerating anti-CD4 mAb, RIB5/2, had virtually no influence on the DTH|The other ameliorating anti-CD4 mAb, W3/25, also induced an increase, but statistical significance was not reached|treatment with the accelerating anti-CD4 mAb, RIB5/2, had virtually no influence on the DTH|6233..6540|6555..6646|6426..6540|6555..6646|111020.txt|6542..6553|PS
T-cell reactivity was investigated on day 13 of AA, i.e. when the clinical differences between the accelerating and ameliorating anti-CD4 mAbs were maximal|the influence of these mAbs on early signaling events was investigated|For IFN-γ, IL-10, and IL-4, see Supplementary material|Because the three anti-CD4 mAbs recognize distinct epitopes of the CD4 molecule, which is involved in signaling cascades, the influence of these mAbs on early signaling events was investigated|6074..6229|7954..8011;8017..8029|7774..7828|7832..8011;8017..8029|111020.txt|8012..8016|PS
Although successful treatment with anti-CD4 mAbs has been achieved in various arthritis models [12,16-18], there is no evidence for a differential efficacy of anti-CD4 mAbs in arthritis models to date|this finding may represent the experimental counterpart of the conflicting results observed thus far in studies of human rheumatoid arthritis [6,8,10]|Although successful treatment with anti-CD4 mAbs has been achieved in various arthritis models [12,16-18], there is no evidence for a differential efficacy of anti-CD4 mAbs in arthritis models to date|this finding may represent the experimental counterpart of the conflicting results observed thus far in studies of human rheumatoid arthritis [6,8,10|9449..9649|9657..9807|9449..9649|9657..9806|111020.txt|9651..9655|PS
the present study did not confirm a role for the mAb isotype in AA, as the isotypes of the three anti-CD4 mAbs did not match their differential preventive effects in AA|a contribution of the strikingly higher kdiss of the mAb RIB5/2 to its differential clinical effects cannot be excluded, in analogy to high and low kdiss for agonistic and antagonistic TCR-peptides, respectively [21]|The ameliorating mAb W3/25 had a very high affinity, as previously reported [20], whereas the affinity of the other ameliorating mAb, OX35, was comparable to that of the accelerating mAb, RIB5/2|a contribution of the strikingly higher kdiss of the mAb RIB5/2 to its differential clinical effects cannot be excluded, in analogy to high and low kdiss for agonistic and antagonistic TCR-peptides, respectively [21|9892..10060|10277..10493|10062..10256|10277..10492|111020.txt|10258..10275|PS
In the present study, the ameliorating anti-CD4 mAbs W3/25 and OX35 (but not the accelerating mAb, RIB5/2) numerically/significantly increased the DTH to the arthritogen M. tuberculosis. In the total T-cell population, two of the three anti-CD4 mAbs (and in purified CD4+ T cells, all three anti-CD4 mAbs) increased the in vitro reactivity to ConA. In the case of CD4+ T cells, this increased reactivity was negatively correlated with the clinical score of individual animals|The successful mode of action of anti-CD4 mAbs in arthritides may be based on increasing the reactivity of a subpopulation of regulatory T cells, an interpretation that is supported by i) the increase of T-cell reactivity in some patients successfully treated with anti-CD4 mAbs [6], ii) an increased DTH to antigens like tetanus toxoid in less active versus active rheumatoid arthritis [25], iii) the reduced responsiveness to poly-specific stimulation of spleen cells from rats with acute AA in comparison with healthy animals [26], and iv) the almost complete restoration of T-cell responsiveness upon disease resolution/transition into the chronic phase [27]|In the case of CD4+ T cells, this increased reactivity was negatively correlated with the clinical score of individual animals|The successful mode of action of anti-CD4 mAbs in arthritides may be based on increasing the reactivity of a subpopulation of regulatory T cells, an interpretation that is supported by i) the increase of T-cell reactivity in some patients successfully treated with anti-CD4 mAbs [6], ii) an increased DTH to antigens like tetanus toxoid in less active versus active rheumatoid arthritis [25], iii) the reduced responsiveness to poly-specific stimulation of spleen cells from rats with acute AA in comparison with healthy animals [26], and iv) the almost complete restoration of T-cell responsiveness upon disease resolution/transition into the chronic phase [27|11465..11940|11942..12007;12018..12614|11814..11940|11942..12007;12018..12613|111020.txt|12008..12017|PS
The differential clinical efficacy of anti-CD4 mAbs is not restricted to arthritis but is also observed in transplantation models [37]|while preventive treatment with the anti-CD4 mAb RIB5/2 leads to an acceleration of AA, it is a very effective anti-CD4 mAb for the induction of tolerance in transplantation models [14,37]|The differential clinical efficacy of anti-CD4 mAbs is not restricted to arthritis but is also observed in transplantation models [37|while preventive treatment with the anti-CD4 mAb RIB5/2 leads to an acceleration of AA, it is a very effective anti-CD4 mAb for the induction of tolerance in transplantation models [14,37|14056..14190|14201..14389|14056..14189|14201..14388|111020.txt|14192..14199|PS
of previous experiments demonstrating its high clinical efficacy in AA [S2]|preventive treatment with an isotype-matched mAb from birth had shown no effect on rat AA in a previous study [S3]|The control group received PBS [S3|preventive treatment with an isotype-matched mAb from birth had shown no effect on rat AA in a previous study [S3|18405..18480|18532..18646|18482..18516|18532..18645|111020.txt|18519..18530|PS
For determination of the arthritis score, each paw was graded according to the extent of erythema and edema of the periarticular tissue, on a scale of 0–4, where 0=no inflammation, 1=unequivocal inflammation of one paw joint, 2=unequivocal inflammation of at least two paw joints or moderate inflammation of one paw joint, 3=severe inflammation of one or more paw joints, and 4=maximum inflammation of one or more paw joints [S4,S5]|The scores were added to obtain the total score (maximal possible score of 16 for each animal)|For determination of the arthritis score, each paw was graded according to the extent of erythema and edema of the periarticular tissue, on a scale of 0–4, where 0=no inflammation, 1=unequivocal inflammation of one paw joint, 2=unequivocal inflammation of at least two paw joints or moderate inflammation of one paw joint, 3=severe inflammation of one or more paw joints, and 4=maximum inflammation of one or more paw joints [S4,S5|The scores were added to obtain the total score (maximal possible score of 16 for each animal)|18650..19082|19084..19099;19105..19183|18650..19081|19084..19099;19105..19183|111020.txt|19100..19104|PS
and the resulting suspension was centrifuged through Lymphoprep (Pharmacia)|Cells contained in the interphase were washed twice and loaded onto a 10-ml syringe with 1.2 g nylon wool (Polyscience, Eppelheim, Germany)|Briefly, the spleens were passed through a stainless steel sieve and the resulting suspension was centrifuged through Lymphoprep (Pharmacia)|Cells contained in the interphase were washed twice and loaded onto a 10-ml syringe with 1.2 g nylon wool (Polyscience, Eppelheim, Germany)|20223..20298|20300..20338;20344..20444|20158..20298|20300..20338;20344..20444|111020.txt|20339..20343|PS
and then centrifuged through 2 ml of a 14.5% metrizamide solution (Sigma) in R10F|DC were irradiated with 15 Gy to prevent their proliferation in subsequent assays|For enrichment of dendritic cells (DC), suspensions of spleen cells from healthy rats were subjected to an overnight adhesion step on Petri dishes (Falcon®, Becton Dickinson, Heidelberg, Germany) and then centrifuged through 2 ml of a 14.5% metrizamide solution (Sigma) in R10F|DC were irradiated with 15 Gy to prevent their proliferation in subsequent assays|21454..21535|21537..21544;21550..21623|21258..21535|21537..21544;21550..21623|111020.txt|21545..21549|PS
For proliferation assays, 1 × 105 purified total or CD4+ spleen T cells per well of 96-well round-bottom plates were incubated with 1 × 104 DC per well and 1 μg/ml ConA (Sigma) for 72 hours|1 μCi/well 3H-thymidine (Amersham-Buchler, Braunschweig, Germany) was added|For proliferation assays, 1 × 105 purified total or CD4+ spleen T cells per well of 96-well round-bottom plates were incubated with 1 × 104 DC per well and 1 μg/ml ConA (Sigma) for 72 hours|1 μCi/well 3H-thymidine (Amersham-Buchler, Braunschweig, Germany) was added|21625..21814|21821..21896|21625..21814|21821..21896|111020.txt|21816..21820|PS
spleen CD4+ T cells were incubated with the anti-CD4 mAbs or isotype control mAbs (10 μg per 1 × 107 cells) for 30 min at 4°C and washed once|The bound mAbs were cross-linked with goat anti-mouse IgG (Jackson Lab, 20 μg/1 × 107 cells) for 1 hour at 37°C|For anti-CD4 preincubation, spleen CD4+ T cells were incubated with the anti-CD4 mAbs or isotype control mAbs (10 μg per 1 × 107 cells) for 30 min at 4°C and washed once|The bound mAbs were cross-linked with goat anti-mouse IgG (Jackson Lab, 20 μg/1 × 107 cells) for 1 hour at 37°C|22817..22958|22960..22979;22985..23076|22789..22958|22960..22979;22985..23076|111020.txt|22980..22984|PS
ConA stimulation of CD4+ T cells resulted in generally lower proliferation rates than those of total T cells in PBS-treated rats|the values of CD4+ T cells from individual, anti-CD4-treated animals were always higher than those of the PBS-treated control group (Supplementary Fig. 3a)|ConA stimulation of CD4+ T cells resulted in generally lower proliferation rates than those of total T cells in PBS-treated rats|the values of CD4+ T cells from individual, anti-CD4-treated animals were always higher than those of the PBS-treated control group (Supplementary Fig. 3a)|26966..27094|27105..27260|26966..27094|27105..27260|111020.txt|27096..27103|PS
The accelerating mAb RIB5/2 led to significant inhibition at all concentrations of mAb (1, 5, and 10 μg/ml; only 1 μg/ml is shown in Supplementary Fig. 4a) and DC, whereas the other two anti-CD4 mAbs significantly inhibited the proliferation only in some cases|RIB5/2 inhibited the proliferation to a statistically significant degree at 1 μg/ml and 2 × 104 DC/well more strongly than both W3/25 and OX35|The accelerating mAb RIB5/2 led to significant inhibition at all concentrations of mAb (1, 5, and 10 μg/ml; only 1 μg/ml is shown in Supplementary Fig. 4a) and DC, whereas the other two anti-CD4 mAbs significantly inhibited the proliferation only in some cases|RIB5/2 inhibited the proliferation to a statistically significant degree at 1 μg/ml and 2 × 104 DC/well more strongly than both W3/25 and OX35|27887..28147|28162..28304|27887..28147|28162..28304|111020.txt|28149..28160|PS
The anti-CD4 mAbs moderately inhibited the proliferation of total spleen T cells, depending on the stimulator cell concentration (Supplementary Fig. 4a). The accelerating mAb RIB5/2 led to significant inhibition at all concentrations of mAb (1, 5, and 10 μg/ml; only 1 μg/ml is shown in Supplementary Fig. 4a) and DC, whereas the other two anti-CD4 mAbs significantly inhibited the proliferation only in some cases. Furthermore, RIB5/2 inhibited the proliferation to a statistically significant degree at 1 μg/ml and 2 × 104 DC/well more strongly than both W3/25 and OX35|these differential results (inversely) match the differential clinical efficacy seen with the three mAbs|Furthermore, RIB5/2 inhibited the proliferation to a statistically significant degree at 1 μg/ml and 2 × 104 DC/well more strongly than both W3/25 and OX35|these differential results (inversely) match the differential clinical efficacy seen with the three mAbs|27733..28304|28312..28416|28149..28304|28312..28416|111020.txt|28306..28310|PS
They showed a clearer inhibition of their proliferation rates (50 to 80% in comparison with the isotype) when used as responder cells|in contrast to the total T-cell population, there was no significant difference in the inhibitory potency among the three anti-CD4 mAbs (Supplementary Fig. 4b)|They showed a clearer inhibition of their proliferation rates (50 to 80% in comparison with the isotype) when used as responder cells|in contrast to the total T-cell population, there was no significant difference in the inhibitory potency among the three anti-CD4 mAbs (Supplementary Fig. 4b)|28620..28753|28764..28923|28620..28753|28764..28923|111020.txt|28755..28762|PS
After treatment with W3/25, the percentage and/or MFI (mean fluorescence intensity) of CD3+ cells in the peripheral blood on days 8 and 13 was numerically lower than in the PBS-treated control group, resulting in a significantly lower MFI on day 13|a decrease of CD4+ cells was observed when the cells were stained with OX35 (more prominent on day 13; see Supplementary Table 2B). After ex vivo staining with W3/25 – the mAb also used for treatment – only 7% (day 8) and 28% (day 13) of the peripheral blood mononuclear cells were CD4+|After treatment with W3/25, the percentage and/or MFI (mean fluorescence intensity) of CD3+ cells in the peripheral blood on days 8 and 13 was numerically lower than in the PBS-treated control group, resulting in a significantly lower MFI on day 13 (note: the fact that on day 8 only two animals of the W3/25-treated group were investigated likely prevented statistical significance)|a decrease of CD4+ cells was observed when the cells were stained with OX35 (more prominent on day 13; see Supplementary Table 2B)|29310..29558|29708..29994|29310..29693|29708..29838|111020.txt|29695..29706|PS
After treatment with W3/25, the percentage and/or MFI (mean fluorescence intensity) of CD3+ cells in the peripheral blood on days 8 and 13 was numerically lower than in the PBS-treated control group, resulting in a significantly lower MFI on day 13 Furthermore, a decrease of CD4+ cells was observed when the cells were stained with OX35 (more prominent on day 13; see Supplementary Table 2B). After ex vivo staining with W3/25 – the mAb also used for treatment – only 7% (day 8) and 28% (day 13) of the peripheral blood mononuclear cells were CD4+ After treatment with W3/25, the percentage of CD8+ cells did not show any significant changes on days 8 or 13; however, the MFI for CD8 on day 13 was significantly decreased (see Supplementary Table 2B)|the anti-CD4 mAb W3/25 induced only weak depletion of CD4+ cells, as indicated by unchanged percentages of CD8+ cells. In addition, there was modulation of the CD4 and co-modulation of the CD3 surface molecules and indirect modulation of the CD8 molecule (see Supplementary Table 2B)|After treatment with W3/25, the percentage of CD8+ cells did not show any significant changes on days 8 or 13; however, the MFI for CD8 on day 13 was significantly decreased (see Supplementary Table 2B)|the anti-CD4 mAb W3/25 induced only weak depletion of CD4+ cells, as indicated by unchanged percentages of CD8+ cells|29310..29558;29695..29994;30222..30424|30439..30722|30222..30424|30439..30556|111020.txt|30428..30437|PS
Therefore, the anti-CD4 mAb W3/25 induced only weak depletion of CD4+ cells, as indicated by unchanged percentages of CD8+ cells|there was modulation of the CD4 and co-modulation of the CD3 surface molecules and indirect modulation of the CD8 molecule (see Supplementary Table 2B)|Therefore, the anti-CD4 mAb W3/25 induced only weak depletion of CD4+ cells, as indicated by unchanged percentages of CD8+ cells|there was modulation of the CD4 and co-modulation of the CD3 surface molecules and indirect modulation of the CD8 molecule (see Supplementary Table 2B)|30428..30556|30571..30722|30428..30556|30571..30722|111020.txt|30558..30569|PS
Therefore, the anti-CD4 mAb W3/25 induced only weak depletion of CD4+ cells, as indicated by unchanged percentages of CD8+ cells. In addition, there was modulation of the CD4 and co-modulation of the CD3 surface molecules and indirect modulation of the CD8 molecule (see Supplementary Table 2B)|The anti-CD4 mAb W3/25 represented a weakly depleting, but modulating antibody|In addition, there was modulation of the CD4 and co-modulation of the CD3 surface molecules and indirect modulation of the CD8 molecule (see Supplementary Table 2B)|The anti-CD4 mAb W3/25 represented a weakly depleting, but modulating antibody|30428..30722|30724..30746;30757..30812|30558..30722|30724..30746;30757..30812|111020.txt|30747..30756|PS
In comparison with W3/25, the mAb OX35 induced a clearer depletion of CD4+ cells of the peripheral blood, as indicated by a significant increase in the percentage of CD8+ cells|the mAb OX35 induced CD4-modulation and CD3-co-modulation, as shown by a profound decrease of CD4+ cells and a decrease of the MFI for CD4|In comparison with W3/25, the mAb OX35 induced a clearer depletion of CD4+ cells of the peripheral blood, as indicated by a significant increase in the percentage of CD8+ cells|the mAb OX35 induced CD4-modulation and CD3-co-modulation, as shown by a profound decrease of CD4+ cells and a decrease of the MFI for CD4|31541..31717|31732..31870|31541..31717|31732..31870|111020.txt|31719..31730|PS
In comparison with W3/25, the mAb OX35 induced a clearer depletion of CD4+ cells of the peripheral blood, as indicated by a significant increase in the percentage of CD8+ cells. In addition, the mAb OX35 induced CD4-modulation and CD3-co-modulation, as shown by a profound decrease of CD4+ cells and a decrease of the MFI for CD4|OX35 represented a depleting and modulating antibody|In addition, the mAb OX35 induced CD4-modulation and CD3-co-modulation, as shown by a profound decrease of CD4+ cells and a decrease of the MFI for CD4|OX35 represented a depleting and modulating antibody|31541..31870|31878..31930|31719..31870|31878..31930|111020.txt|31872..31876|PS
RIB5/2 also induced a significant reduction of CD3+ cells in comparison with the PBS group (see Supplementary Table 2A,B). The percentage of CD4+ cells was also significantly decreased on days 8 and 13|there was a significant increase of CD8+ cells in the periphery of RIB5/2-treated rats in comparison with the PBS-treated control (see Supplementary Table 2A,B).|The percentage of CD4+ cells was also significantly decreased on days 8 and 13|there was a significant increase of CD8+ cells in the periphery of RIB5/2-treated rats in comparison with the PBS-treated control (see Supplementary Table 2A,B)|31934..32135|32150..32311|32057..32135|32150..32310|111020.txt|32137..32148|PS
Similarly to the findings for mAb OX35, mAb RIB5/2 induced T-cell depletion and CD4 modulation; however, the degree of peripheral T-cell depletion was stronger than in the case of OX35|since both ameliorating and accelerating mAbs (OX35 and RIB5/2) depleted CD4+ T cells from peripheral blood, and since all three mAbs were modulating, there was no apparent match of these parameters with the clinical efficacy|Similarly to the findings for mAb OX35, mAb RIB5/2 induced T-cell depletion and CD4 modulation; however, the degree of peripheral T-cell depletion was stronger than in the case of OX35|since both ameliorating and accelerating mAbs (OX35 and RIB5/2) depleted CD4+ T cells from peripheral blood, and since all three mAbs were modulating, there was no apparent match of these parameters with the clinical efficacy|32312..32496|32506..32731|32312..32496|32506..32731|111020.txt|32500..32504|PS
The anti-CD4 mAb W3/25 induced a significantly higher percentage of IL-4-positive cells at 24 and 48 hours than did the isotype control (Supplementary Fig. 5d); the MFI was also significantly higher in comparison with OX35 and RIB5/2 (Supplementary Fig. 5e).|there were no significant differences of the IL-4 concentration in the supernatant of the cultures (Supplementary Fig. 5f)|The anti-CD4 mAb W3/25 induced a significantly higher percentage of IL-4-positive cells at 24 and 48 hours than did the isotype control (Supplementary Fig. 5d); the MFI was also significantly higher in comparison with OX35 and RIB5/2 (Supplementary Fig. 5e)|there were no significant differences of the IL-4 concentration in the supernatant of the cultures (Supplementary Fig. 5f)|33114..33372|33386..33508|33114..33371|33386..33508|111020.txt|33373..33384|PS
At 24 h, a numerical increase of the percentage of IL-10-positive cells could be detected after preincubation with the ameliorating mAb W3/25 and the accelerating mAb RIB5/2, whereas the other ameliorating mAb, OX35, induced a significant increase (Supplementary Fig. 5g). This increase was no longer observed at 48 h (Supplementary Fig. 5g)|the MFI for IL-10 was increased both 24 h and 48 h after pretreatment with anti-CD4 mAbs|This increase was no longer observed at 48 h (Supplementary Fig. 5g)|the MFI for IL-10 was increased both 24 h and 48 h after pretreatment with anti-CD4 mAbs|33627..33968|33983..34071|33900..33968|33983..34071|111020.txt|33970..33981|PS
Preincubation with all anti-CD4 mAbs induced a significantly higher secretion of IL-10 than did the isotype control, not only after 24 h, but also after 48 hours|None of the parameters showed significant differences among the three different anti-CD4 mAbs (Supplementary Fig. 5i)|Preincubation with all anti-CD4 mAbs induced a significantly higher secretion of IL-10 than did the isotype control, not only after 24 h, but also after 48 hours (the latter increase did not reach statistical significance in the case of OX35)|None of the parameters showed significant differences among the three different anti-CD4 mAbs (Supplementary Fig. 5i)|34235..34396|34479..34501;34512..34606|34235..34477|34479..34501;34512..34606|111020.txt|34503..34510|PS
Because depletion/modulation in peripheral blood may differ from that in other compartments (e.g. lymphoid organs), the use of the terms 'depleting' or 'nondepleting' has to be restricted to the blood|In the case of the mAbs W3/25 and OX35 studies with marked, antibody-coated cells indicate a redistribution of the cells from lymphoid organs to the liver, possibly including phagocytosis and depletion of the opsonized 'cells' by liver macrophages (unpublished observations)|Because depletion/modulation in peripheral blood may differ from that in other compartments (e.g. lymphoid organs), the use of the terms 'depleting' or 'nondepleting' has to be restricted to the blood|In the case of the mAbs W3/25 and OX35 studies with marked, antibody-coated cells indicate a redistribution of the cells from lymphoid organs to the liver, possibly including phagocytosis and depletion of the opsonized 'cells' by liver macrophages (unpublished observations)|35364..35564|35566..35604;35615..35850|35364..35564|35566..35604;35615..35850|111020.txt|35606..35613|PS
Treatment with W3/25 and OX35 significantly suppressed AA from day 13 until day 30|RIB5/2 accelerated the onset of AA by 2 days and led to significant improvement only in the late phase (from day 27)|Treatment with W3/25 and OX35 significantly suppressed AA from day 13 until day 30|RIB5/2 accelerated the onset of AA by 2 days and led to significant improvement only in the late phase (from day 27)|38502..38584|38599..38715|38502..38584|38599..38715|111020.txt|38586..38597|PS
Inflammatory cell infiltrate consisted of CD4-Mac1+ macrophages|Depletion of monocytes was not enough to abolish inflammation|Inflammatory cell infiltrate consisted of CD4-Mac1+ macrophages|Depletion of monocytes was not enough to abolish inflammation|933..996|998..1024;1035..1069|933..996|998..1024;1035..1069|111021.txt|1026..1033|PS
Depletion of monocytes was, however, not enough to abolish inflammation|combined deficiency of monocytes and lymphocytes was required to prevent inflammation following the injection of TF|Depletion of monocytes was, however, not enough to abolish inflammation|combined deficiency of monocytes and lymphocytes was required to prevent inflammation following the injection of TF|998..1069|1079..1194|998..1069|1079..1194|111021.txt|1071..1077|PS
T cells regulate TF expression: upregulation is achieved by Th1 cytokines, while Th2-derived cytokines are mostly inhibitory [11]|TF may participate in cellular interactions promoting leukocyte adhesion and transendothelial migration [12,13]|T cells regulate TF expression: upregulation is achieved by Th1 cytokines, while Th2-derived cytokines are mostly inhibitory [11|TF may participate in cellular interactions promoting leukocyte adhesion and transendothelial migration [12,13|2511..2640|2642..2644;2655..2763|2511..2639|2642..2644;2655..2762|111021.txt|2646..2653|PS
No significant difference in the results obtained with these two preparations was observed|and the results were pooled|Two preparations of TF were used that contained 3.7 μg/ml and 32 ng/ml of lipopolysaccharide (LPS), respectively|No significant difference in the results obtained with these two preparations was observed and the results were pooled|4100..4190|4191..4211;4217..4223|3986..4098|4100..4211;4217..4223|111021.txt|4212..4216|PS
The arthritis index of the rTF-induced arthritis was significantly higher in joints injected with 20 μg of rTF than in the controls (1.73 versus 0.23; P < 0.01)|6/13 joints injected with 20 μg of rTF developed extrasynovial features of arthritis (pannus formation, n = 2; cartilage destruction, n = 3 and periarticular bone destruction, n = 1) compared to only one in the control group|The arthritis index of the rTF-induced arthritis was significantly higher in joints injected with 20 μg of rTF than in the controls (1.73 versus 0.23; P < 0.01)|6/13 joints injected with 20 μg of rTF developed extrasynovial features of arthritis (pannus formation, n = 2; cartilage destruction, n = 3 and periarticular bone destruction, n = 1) compared to only one in the control group|8684..8844|8856..9080|8684..8844|8856..9080|111021.txt|8846..8854|PS
Immunochemical staining of joint sections revealed dense infiltrates consisting of Mac-1+ mononuclear cells in the synovial tissue|all the sections were negative for staining with CD4-specific antibodies|Immunochemical staining of joint sections revealed dense infiltrates consisting of Mac-1+ mononuclear cells in the synovial tissue|all the sections were negative for staining with CD4-specific antibodies|9984..10114|10129..10201|9984..10114|10129..10201|111021.txt|10116..10127|PS
The increase was pronounced for MIP-1α (73 ± 33 pg/ml in non-stimulated cells versus 139 ± 32 pg/ml after stimulation with 5 μg/ml of rTF; n = 3) but was only marginal for RANTES (256 ± 46 pg/ml versus 365 ± 32 pg/ml; n = 3)|neither change in the level of IL-6 nor proliferation of lymphocytes was observed|The increase was pronounced for MIP-1α (73 ± 33 pg/ml in non-stimulated cells versus 139 ± 32 pg/ml after stimulation with 5 μg/ml of rTF; n = 3) but was only marginal for RANTES (256 ± 46 pg/ml versus 365 ± 32 pg/ml; n = 3)|neither change in the level of IL-6 nor proliferation of lymphocytes was observed|12232..12456|12471..12552|12232..12456|12471..12552|111021.txt|12458..12469|PS
An indication of the importance of TF in the inflammatory process was obtained in the animal model of sepsis, in which TF-dependent procoagulant activity correlated with the level of tumor necrosis factor-α [23]|modulation of TF-dependent coagulation by administration of either TF-pathway inhibitor or anti-TF antibodies decreased circulating levels of IL-6 and IL-8 [24,25], and diminished proliferation and perivascular cell infiltration [26,27]|An indication of the importance of TF in the inflammatory process was obtained in the animal model of sepsis, in which TF-dependent procoagulant activity correlated with the level of tumor necrosis factor-α [23|modulation of TF-dependent coagulation by administration of either TF-pathway inhibitor or anti-TF antibodies decreased circulating levels of IL-6 and IL-8 [24,25], and diminished proliferation and perivascular cell infiltration [26,27|12934..13145|13160..13396|12934..13144|13160..13395|111021.txt|13147..13158|PS
Mononuclear cell influx into synovia is an early finding in the majority of asymptomatic subjects, preceding clinically overt arthritis in RA [28,29]|synovial macrophage infiltration is a characteristic feature of both autoimmune and bacterial arthritis [30,31] and is a determinant of joint erosions [32,33]|Mononuclear cell influx into synovia is an early finding in the majority of asymptomatic subjects, preceding clinically overt arthritis in RA [28,29|synovial macrophage infiltration is a characteristic feature of both autoimmune and bacterial arthritis [30,31] and is a determinant of joint erosions [32,33|13613..13762|13777..13935|13613..13761|13777..13934|111021.txt|13764..13775|PS
Composition of inflammatory infiltrate and cell depletion studies showed that TF exerts its proinflammatory properties in a cell-specific manner targeting the macrophage/ monocyte population|we demonstrated that an interaction between monocytes and lymphocytes was a prerequisite of the TF-induced arthritis|This is not surprising taking into consideration that macrophages/monocytes are the only cells in the blood circulation compartment which express TF on their surface [8,34|we demonstrated that an interaction between monocytes and lymphocytes was a prerequisite of the TF-induced arthritis|14205..14395|14581..14697|14397..14568|14581..14697|111021.txt|14571..14579|PS
TF may attract Mac-1+ cells indirectly by increasing formation of coagulation proteins known as Mac-1 ligands, e.g. Factor X and fibrinogen|the high incidence of TF-induced arthritis in defibrinated mice favors a direct stimulatory effect of TF on sensitive cells|TF may attract Mac-1+ cells indirectly by increasing formation of coagulation proteins known as Mac-1 ligands, e.g. Factor X and fibrinogen|the high incidence of TF-induced arthritis in defibrinated mice favors a direct stimulatory effect of TF on sensitive cells|15429..15568|15579..15702|15429..15568|15579..15702|111021.txt|15570..15577|PS
